| Steven O Anderson, MD | |
|
2020 Philadelphia St, Ames, IA 50010 | |
| (515) 232-2450 | |
| Not Available |
| Full Name | Steven O Anderson |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 32 Years |
| Location | 2020 Philadelphia St, Ames, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942288717 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 45326 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Trinity Regional Medical Center | Fort dodge, IA | Hospital |
| Mary Greeley Medical Center | Ames, IA | Hospital |
| Van Diest Medical Center | Webster city, IA | Hospital |
| Hansen Family Hospital | Iowa falls, IA | Hospital |
| Story County Hospital | Nevada, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wolfe Clinic Inc | 8628979291 | 47 |
News Archive
Japanese research group led by Prof. Makoto Tominaga and Dr. Takaaki Sokabe (National Institute for Physiological Sciences: NIPS) found that TRPV4 ion channel in skin keratinocytes is important for formation and maintenance of barrier function to prevent dehydration. Their finding was reported in the Journal of Biological Chemistry.
People experiencing sudden cardiac arrest at exercise facilities have a higher chance of survival than at other indoor locations, likely due to early CPR and access to an automated external defibrillator, among other factors, according to a study published online today in the Journal of the American College of Cardiology.
Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its AZ-004 New Drug Application (NDA) to the U.S. Food and Drug Administration in response to a Complete Response Letter (CRL) received in October 2010.
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
Extracellular vesicles (EVs) - nanometer sized messengers that travel between cells to deliver cues and cargo - are promising tools for the next generation of therapies for everything from autoimmune and neurodegenerative diseases to cancer and tissue injury.
› Verified 3 days ago
| Entity Name | Wolfe Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477532174 PECOS PAC ID: 8628979291 Enrollment ID: O20040116000276 |
News Archive
Japanese research group led by Prof. Makoto Tominaga and Dr. Takaaki Sokabe (National Institute for Physiological Sciences: NIPS) found that TRPV4 ion channel in skin keratinocytes is important for formation and maintenance of barrier function to prevent dehydration. Their finding was reported in the Journal of Biological Chemistry.
People experiencing sudden cardiac arrest at exercise facilities have a higher chance of survival than at other indoor locations, likely due to early CPR and access to an automated external defibrillator, among other factors, according to a study published online today in the Journal of the American College of Cardiology.
Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its AZ-004 New Drug Application (NDA) to the U.S. Food and Drug Administration in response to a Complete Response Letter (CRL) received in October 2010.
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
Extracellular vesicles (EVs) - nanometer sized messengers that travel between cells to deliver cues and cargo - are promising tools for the next generation of therapies for everything from autoimmune and neurodegenerative diseases to cancer and tissue injury.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven O Anderson, MD 309 E Church St, Marshalltown, IA 50158-2946 Ph: () - | Steven O Anderson, MD 2020 Philadelphia St, Ames, IA 50010 Ph: (515) 232-2450 |
News Archive
Japanese research group led by Prof. Makoto Tominaga and Dr. Takaaki Sokabe (National Institute for Physiological Sciences: NIPS) found that TRPV4 ion channel in skin keratinocytes is important for formation and maintenance of barrier function to prevent dehydration. Their finding was reported in the Journal of Biological Chemistry.
People experiencing sudden cardiac arrest at exercise facilities have a higher chance of survival than at other indoor locations, likely due to early CPR and access to an automated external defibrillator, among other factors, according to a study published online today in the Journal of the American College of Cardiology.
Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its AZ-004 New Drug Application (NDA) to the U.S. Food and Drug Administration in response to a Complete Response Letter (CRL) received in October 2010.
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
Extracellular vesicles (EVs) - nanometer sized messengers that travel between cells to deliver cues and cargo - are promising tools for the next generation of therapies for everything from autoimmune and neurodegenerative diseases to cancer and tissue injury.
› Verified 3 days ago
Dr. Linda Jane Lehman, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1128 Duff Ave, Ames, IA 50010 Phone: 515-239-4460 Fax: 515-956-4145 | |
Louis J Scallon, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2020 Philadelphia St, Ames, IA 50010 Phone: 515-232-2450 Fax: 515-232-3532 | |
Daniel J Vos, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2020 Philadelphia St, Ames, IA 50010 Phone: 515-232-2450 | |
Dr. Kenneth Earl Talbert, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1128 Duff Ave, Ames, IA 50010 Phone: 515-239-4460 Fax: 515-239-4437 | |
Ryan David Vincent, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2020 Philadelphia St, Ames, IA 50010 Phone: 515-232-2450 Fax: 515-232-3532 | |
Tracy Anne Kangas, MD PHD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1128 Duff Avenue, Mcfarland Clinic Pc, Ames, IA 50010 Phone: 515-239-4460 Fax: 515-956-4145 | |
Dr. Nicolas George Hamouche, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1128 Duff Ave, Ames, IA 50010 Phone: 515-663-4888 Fax: 515-956-4199 |